Startseite Medizin Is BaF3 Bioassay Useful to Identify Patients with Bioinactive Growth Hormone?
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Is BaF3 Bioassay Useful to Identify Patients with Bioinactive Growth Hormone?

  • Sara Pagani , Eduardo A. Chaler , Cristina Meazza , Mercedes Maceiras , Maria Eugenia Gonzalez , Marco A. Rivarola , Francesca Cantoni , Paola Travaglino , Lucia Della Croce , Kamilia Laarej , Mauro Bozzola und Alicia Belgorosky
Veröffentlicht/Copyright: 17. September 2010
Journal of Pediatric Endocrinology and Metabolism
Aus der Zeitschrift Band 23 Heft 8

ABSTRACT

We analyzed the ability of the BaF3 cell line bioassay to select patients with biologically inactive GH. We first evaluated the biological response of the Ba/F3-hGHR cells to rhGH additional doses from 10 to 5000 pg/ml. The concentration points corresponding to the linear part of the curve were selected. We then analyzed a group of sera, diluted like the standard, including the entire range of GH concentrations that can be analyzed by bioassay. The serum/standard area below the curve ratio was calculated. Serum GH immunoactivity determined by IMMULITE/GH bioactivity ratios was calculated. Our experimental data showed that GH-bioactivity/GH-immunoactivity ratios below 0.303 are indicative of a bioinactive GH molecule. This bioassay would recognize only extreme cases of GH bioinactivity, and it would not be a useful tool in the search for patients with altered forms of GH.


Corresponding author: Mauro Bozzola,

Published Online: 2010-09-17
Published in Print: 2010-August

© Freund Publishing House Ltd. 2010

Heruntergeladen am 19.12.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem.2010.128/pdf?lang=de
Button zum nach oben scrollen